glycogen synthase kinase-3 inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameglycogen synthase kinase-3 inhibitors (Boehringer Ingelheim)
Drug Alias NameBI-5521
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 degraders
TargetsGlycogen synthase kinase-3
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A